Ocugen, Inc. (OCGN)

2.1700 +0.0900 (+4.33%) At close: 04:00PM EDT

Ocugen, Inc.

263 Great Valley Parkway
Suite 160
Malvern, PA 19355
United States
484 328 4701
https://www.ocugen.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 56

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Shankar Musunuri M.B.A., MBA, Ph.D.	Co-Founder, Chairman & CEO	845.2k	6.67M	1964
Dr. Uday B. Kompella Ph.D.	Co-founder & Independent Director	44k	N/A	1967
Dr. Vijay Tammara Ph.D.	Sr. VP of Regulatory & Quality	490.92k	575.63k	1960
Ms. Jessica Crespo CPA, CPA	Chief Accounting Officer, Sr. VP of Fin. and VP of Corp. Controller & Treasurer	N/A	N/A	1977
Mr. J. P. Gabriel	Sr. VP of Technical Operations	N/A	N/A	N/A
Mr. Ken Inchausti	Head of Investor Relations & Communications	N/A	N/A	N/A
Dr. Nirdosh Jagota Ph.D.	Sr. VP of Regulatory Affairs, Compliance & Safety	N/A	N/A	N/A
Ms. Zara Gaudioso	AVP, Head of HR & Chief of Staff	N/A	N/A	N/A
Dr. Arun Upadhyay Ph.D.	Sr. VP of R&D	N/A	N/A	N/A
Dr. Bruce D. Forrest B.S., M.B.A., M.D.	Acting Chief Medical Officer & Vaccine Scientific Advisory Board Member	N/A	N/A	1963

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Corporate governance

Ocugen, Inc.’s ISS governance QualityScore as of 1 May 2022 is 8. The pillar scores are Audit: 6; Board: 8; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.